Kornimate/medical-research-clean huggingface dataset:
minocycline's effects on alcohol responses in humans

Conditions: Alcohol Dependence

Summary: this is a double-blind, placebo-controlled, outpatient study with a between-groups design. sixty male and female heavy social drinkers will be randomly assigned to minocycline (200 or 400 mg/day) or placebo for 10 days. in the first 7 days of treatment, subjects will have 3 outpatient visits for medication administration, dispensing of take-home doses and monitoring of any adverse effects from study medications. on days 8 and 10 of treatment, subjects will have 2 laboratory sessions where alcohol or placebo will be administered intravenously using a clamp procedure. alcohol administration will use a breath alcohol concentration (brac) method, targeting 100 mg %. the alcohol clamp procedure will allow collection of multiple outcome measures including subjective, motor, cognitive measurement and plasma cytokine levels.


Eligibility criteria:
inclusion criteria: 1. male and females, between the ages of 21 and 50; 2. heavy social drinkers who are defined as consuming ≥10 standard alcoholic drinks per week with one to five weekly "binge" drinking episodes, (5 plus drinks per occasion for men; 4 plus drinks for women). no maximum level of alcohol consumption will be defined a priori but individuals who met current dsm -iv criteria for aud will be excluded from the study; 3. no current drug use disorder of any drugs of abuse (except alcohol and tobacco); 4. no current medical problems and normal ecg; 5) for women, not pregnant as determined by pregnancy screening nor breast feeding, and using acceptable birth control methods. exclusion criteria: 1. current major psychiatric illnesses including mood, psychotic, or anxiety disorders; 2. history of major medical illnesses; including liver diseases, heart disease, chronic pain or other medical conditions that the physician investigator deems contraindicated for the subject to be in the study; 3. liver function tests (alt or ast) greater than 3 times normal; 4. allergy to minocycline or other tetracyclines; 5. participants who at any appointment have a clinical institute withdrawal assessment scale (ciwa) \[36, 37\] score of 4 or greater, or who report any history of alcohol withdrawal within the past 6 months.

Keywords: alcohol dependence minocycline
subendocardial viability ratio in hypertension

Conditions: Hypertension

Summary: the aim of the research is to evaluate the subendocardial viability ratio (sevr) in hypertensive patients, using non-invasive arterial tonometry, and to establish the influencing factors and the possibility of predicting cardiovascular morbidity and mortality in arterial hypertension. the sevr will be evaluated on all patients belonging to the arterial hypertension centers undergoing non-invasive arterial tonometry. the sevr is calculated on the morphology of the central pressure wave as the ratio between the dpti (diastolic pressure-time index), i.e. the area between the carotid pressure curve and the ventricular pressure curve during the diastolic phase, and the spti ( systolic pressure-time index), i.e. the area under the carotid pressure curve during the systolic phase. the sevr will be correlated with the anthropometric and pathology variables which will be collected in an appropriate database.


Eligibility criteria:
inclusion criteria: * hypertension exclusion criteria: * atrial fibrillation

Keywords: myocardial ischemia buckberg index
lymphedema screening

Conditions: Lymphedema

Summary: breast cancer-related lymphedema is one of the most common and feared consequences of breast cancer treatment. currently, there is no established screening program for lymphedema. this cross-sectional study will investigate diagnostic modalities in screening for lymphedema in patients with and without known lymphedema after breast cancer.


Eligibility criteria:
inclusion criteria: * previous breast cancer treated with axillary lymph node dissection * no recurrence * understand the study * can talk, read and understand danish exclusion criteria: * pregnant or breast feeding * lymph node dissection from other basins * psychiatric disorder * not possible to perform indocyanine green lymphangiography
naldebain® extended-release injection after cesarean section in pain management

Conditions: Post Operative Pain; Caesarean Section; Analgesia

Summary: cesarean section is one of the surgeries most commonly leading to postoperative severe acute pain. it was reported that the mean worst pain intensity reached to 6.14 one day after cesarean section in germany. inadequate pain management may result in the cardiorespiratory complications, late recovery, and postoperative chronic pain. according to a series of pain management article published in the lancent in 2019, the incidence of post-cesarean section chronic pain was 55%, including 12% of severe chronic pain. extended-release dinalbuphine sebacate, a prodrug of nalbuphine, is a novel analgesic developed in taiwan and the indication is moderate to severe postoperative pain. after intramuscular injected, dinalbuphine sebacate will be released to blood stream and immediately hydrolyzed. in taiwan, dinalbuphine sebacate has been used for alleviating pain after several types of surgeries, such as colorectal surgery, orthopaedics, gynecology and obstetrics. however, few post-marketing studies investigated the efficacy and safety of dinalbuphine sebacate.

this is an observational, prospective, single arm study. this study is aimed to investigate the efficacy and safety of dinalbuphine sebacate in subjects undergoing cesarean section. written informed consent are obtained before subjects participate in the study. eligible subjects will be visited twice daily during stay in hospital. pain intensity, consumption of analgesics, adverse reaction, and the residues of dinalbuphine sebacate and nalbuphine in milk will all be analyzed.

Eligibility criteria:
inclusion criteria: 1. female aged 20 to 45 years. 2. going to have cesarean section and use dinalbuphine sebacate to alleviate postoperative pain. 3. cesarean section scheduled between the 34th and 41st week of gestation. 4. asa i or ii. 5. willing to comply with study protocol and give written informed consent. exclusion criteria: 1. with contraindication to opioids. 2. chronic use or abuse of opioids. 3. underlying disease which contribute to abnormal lactation, such as mastitis. 4. diagnosed with gestational diabetes mellitus and administration of insulin is required. 5. diagnosed with pre-eclampsia or eclampsia. 6. unsuitable for participation judged by investigator.

Keywords: dinalbuphine sebacate naldebain extended-release analgesics
a study of the effects of inhibiting platelet function on circulating cancer cells in breast cancer patients

Conditions: Breast Neoplasms

Summary: the purpose of this study is to determine the effects of plavix and aspirin in women with metastatic breast cancer.


Eligibility criteria:
inclusion criteria: * women with metastatic breast cancer who are completing planned course of chemotherapy with planned treatment break * on stable hormone therapy for at least 2 months are also eligible for the study * estimated survival of at least 3 months * no platelet inhibitor therapy within 1 month of study entry * platelets ≥ 100,000 * coagulation screening tests within normal range (inr between 0.81 and 1.20) * normal kidney and liver function as defined by: * aspartate aminotransferase(ast)/serum glutamic oxaloacetic transaminase (sgot))/alanine aminotransferase(alt) ≤ 2 x institutional normal * creatinine ≤ 2 x institutional normal * able to provide signed, informed consent. exclusion criteria: * patients going on to surgery * patients with a serious bleeding disorder that make them inappropriate candidates for nsaid therapy * patients with history of significant bleeding related to peptic ulcer disease * patients on standing doses of nsaids or platelet function inhibitors * patients on standing doses of anti-coagulants

Keywords: breast cancer metastatic platelet
effects of emono in children during dental care

Conditions: Dental Care

Summary: the main objective of this project is to evaluate the effects sought and the effects felt by children when emono is used in pediatric dental care. the investigators will try to characterize the children who have submitted a request to extend contact with emono. the maintenance of a framework for the safe use of this drug whose place in dental care is fundamental and the benefit ratio is very favorable is essential.

some narcotic drugs and psychotropic drugs associated with a risk of misuse or identified dependence and are, moreover, the object of a reinforced surveillance. this is the case of emono (equimolar oxygen and nitrogen protoxide mix), which is part of the ansm (french national agency for medicines and health products safety) list of drugs with enhanced surveillance. emono is a gas composed equally of oxygen and nitrous oxide (also called laughing gas). he has had a marketing authorization in france since 2001. until 2009, it was reserved for hospital use. since 2009, a modification of its ma has enabled the release of the hospital reserve, emono can now be used in city medicine and dental surgery. the ansm has made its provision outside health facilities conditional on the implementation of a common national rmp, accompanied by a national monitoring of pharmacovigilance and addictovigilance. the latter is under the responsibility of ceip-a of nantes. the use of emono in pediatric dental care is a particular mode of use in a pediatric population in which the administration of emono is often the first administration of a psychoactive substance known for its positive effects (euphoria). health professionals daily observe children, who after care under emono, have a strong appetite for emono and claim for any intervention. it would be necessary to understand why, and to estimate the number of children involved. do children feel positive effects during these actions, which could lead to a wish to prolong the contact with the gas, in search of an effect other than therapeutic? the main objective of this project is to evaluate the effects sought and the effects felt by children when emono is used in pediatric dental care. the investigators will try to characterize the children who have submitted a request to extend contact with emono. the maintenance of a framework for the safe use of this drug whose place in dental care is fundamental and the benefit ratio is very favorable is essential.

Eligibility criteria:
inclusion criteria: * children aged 3 to 15, requiring care under meopa exclusion criteria: * do not fit into the inclusion criteria

Keywords: equimolar mixture of oxygen and nitrous oxide (emono) substance-related disorders
echocardiographic prediction of fluid responsiveness after a mini-fluid challenge in non-ventilated patients with shock

Conditions: Shock; Circulatory Failure

Summary: the main objective of this study is to show that the variation of the subaortic velocity time integral after a mini test by filling 100 cc of normal saline over 1 minute (δitv100) is predictive of response to filling (defined as an increase in aortic velocity time integral measured by transthoracic ultrasound over 15% after administration of 500 cc of normal saline over 15 minutes) in non-ventilated shock patients.

the secondary objectives of this study include: * to determine the sensitivity and specificity of the variation of the velocity time integral after administration of 100 cc of normal saline over 1 minute (δitv100) to predict the response to the filling. * to study the inter-observer variation of δitv100 measurement. * to compare δitv100 to other clinical and radiological parameters for predicting response to filling (initial value of the subaortic velocity time integral, variation in mitral e wave, e / a, respiratory variation of the diameter of the inferior vena cava, marbling clinical evolution score.

Eligibility criteria:
inclusion criteria: * the patient must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * systolic blood pressure (sbp) \< 90 mmhg * signs of inadequate cardiac output: urine output \<0.5 ml / kg / h for more than two hours, hyperlactataemia * requires amines to maintain an sbp ≥ 90 mmhg or inability to lower amines or requires an increase in amines exclusion criteria: * the patient is participating in another study * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, under tutorship or curatorship * the patient (or his/her person-of-trust) refuses to sign the consent * it is impossible to correctly inform the patient * the patient is pregnant, parturient, or breastfeeding * the patients has a contraindication for a treatment necessary for this study * cardiogenic shock * acute pulmonary edema * moribund patient * non echogenic patient * patient with cardiac arrhythmia * patients for whom the passive leg raising test is contraindicated (hyper intra-abdominal pressure, pelvic or lower limb trauma)

Keywords: mini fluid challenge subaortic velocity time integral
effects of metformin vs oral contraceptives on cv risk markers in pcos

Conditions: Polycystic Ovary Syndrome

Summary: cardiovascular risk factors cluster in hyperandrogenic women - including those presenting with the polycystic ovary syndrome - in association with insulin resistance, obesity, and other metabolic disorders. the present clinical trial intends to compare the effects of oral contraceptives and metformin on pcos patients, focusing on classic and non-classic cardiovascular risk markers and indexes of cardiovascular performance, in order to whether or not, as suspected by previous data obtained in non-hyperandrogenic women, oral contraceptives worsen the cardiovascular risk profile of pcos women, favoring the use of metformin if the latter actually ameliorates such a risk.


Eligibility criteria:
inclusion criteria: * women of fertile age presenting with pcos * non-hyperandrogenic women of fertile age (these women will not receive the interventions and will serve only to obtain normative data for some variables) exclusion criteria: * severe disease not related to the condition under study * pregnancy * medical or surgical treatment of pcos during the previous 3 months * contraindication for the use of oral contraceptives or metformin * inability to understand the proposal of the study precluding effective informed consent * minors who are not accompanied by their legal representative

Keywords: polycystic ovary syndrome hyperandrogenism hirsutism cardiovascular risk chronic inflammation metformin cyproterone acetate oral contraceptives
safety of allogeneic human umbilical cord mesenchymal stem cells (uc-mscs) to treat perianal fistulas w/ crohn's disease

Conditions: Perianal Fistula Due to Crohn's Disease; Fistula in Ano

Summary: objectives: primary: to demonstrate the safety of allogeneic uc-mscs administered by injection for complex perianal fistulas in patients with crohn's disease secondary: to determine the efficacy of a single/multiple allogeneic uc-mscs injection in improving complex perianal fistula complications and (re-epithelialization of the external openings).

design and investigation: number of patients: 5 (including a consideration of 20% \[1 patient\] dropout from the trial) dosage and mode of administration dosage: a total of 60 million pf2020-cell (uc-mscs) will be injected locally around the fistula tract, with a separation of 1 cm between injections. all patients will receive a total of 60 million cells per visit for 5 visits, with a 6 - 12 weeks interval between the injections. if the patient is completely healed during any course of stem cell injections, subsequent stem cell treatments can be discontinued. however, patients will still be required to undergo regular follow-up examinations, including physical examinations and other medical tests, until the study is completed. mode of administration: the procedure involves localizing the fistulous tract, performing curettage and closing the internal opening, and the injection of pf2020-cell (uc-mscs). the indicated dose of pf2020-cell (uc-mscs) will be injected starting from the tissues around the internal orifice or orifices and then progressing towards the external opening.

Eligibility criteria:
inclusion criteria: * adult men and women age 18 years and above. * diagnosis of perianal fistulae associated with crohn's disease refractory to medical therapy. * presence of perianal fistula(s) with a maximum of 2 internal openings and a maximum of 3 external openings based on clinical assessment. * fit for surgery. exclusion criteria: * informed consent refusal. * pregnancy or breastfeeding women. * current diagnosis of active cancer or remission for less than 5 years. * evidence of active sepsis or significant localised infection. * patients with hiv, hbv, hcv or treponema infection, whether active or latent. * patients with documented allergies. * patients who have received infliximab or any other biologics in the 4 weeks before the cell treatment administration. * patients currently receiving, or having received within 1 month prior to enrollment into this clinical trial, any investigational drug. * patients with any other co-morbidity/ co-pathologies which is deemed as contraindication to stem cells infusion (infection, administration of steroids).

Keywords: perianal fistula crohn's disease umbilical cord mesenchymal stem cells (uc-mscs) allogeneic stem cells
the safety and antibody response of the nasal cov2 vaccine against the sars-cov-2 virus

Conditions: COVID19, Sars-Cov-2

Summary: cov2 is a nasal, investigational vaccine against covid-19, based on a serotype 5 adenoviral vector producing the sars-cov-2 spike protein. in this trial, the primary comparison in terms of safety and immunogenicity will be between two different dose levels of cov2 booster vaccine (low, high), and two different administration methods (nasal drops, nasal spray). in addition, cov2 vaccine will also be evaluated in vaccine naive subjects.


Eligibility criteria:
inclusion criteria 1. has voluntarily signed the written informed consent 2. 18-75 years old 3. good general health 4. a) prior vaccination with at least two doses of any covid-19 vaccine, or b) no prior covid-19 vaccination exclusion criteria 1. pregnant, planning to become pregnant or breastfeeding women 2. covid-19 infection within the last nine (9) months 3. any other vaccination within the last two (2) months

Keywords: nasal vaccine adeno-vectored vaccine mucosal vaccine sars-cov-2 covid19
healthy adult male facial skin surface lipid pheromone p.o. to treat opioid addiction

Conditions: Opioid Addiction; Opioid Abuse, Continuous Use; Opioid Use; Opioid-Related Disorders; Paternal Pheromone Deficiency; Opioid Dependence; Opioid Abuse; Opioid-use Disorder; Opioid Intoxication; Opioid Abuse, Episodic

Summary: healthy adult human male facial skin surface lipid liquid pheromone given by mouth to opioid addicts cures them without any withdrawal symptoms whatsoever 250mg on chewing gum vehicle by mouth. elevated mood eventually becomes accommodated after a few weeks. the pheromone contains volatile airborne sub-pheromones which cause aversive behavior (distrust, superstition, suspicion, arrogance, astonishment/stupidity, jealousy). artificial jealousy can be avoided by patient isolation for 40 days until the pheromone "taste" wears off the saliva. the pheromone provided is odorless, colorless, and tasteless to the conscious brain.

healthy adult human male facial skin surface lipid liquid pheromone given by mouth to opioid addicts cures them without any withdrawal symptoms whatsoever 250mg on chewing gum vehicle by mouth. elevated mood eventually becomes accommodated after a few weeks. the pheromone contains volatile aversive sub-pheromones which cause aversive behavior (distrust, superstition, suspicion, arrogance, astonishment/stupidity, jealousy). artificial jealousy can be avoided by patient isolation for 40 days until the pheromone "taste" wears off the saliva. the pheromone provided is odorless, colorless, and tasteless to the conscious brain. pheromone action is insidious. the lifting of the appetite for addictive drugs "monkey on the back" feeling is gratifying. ambition returns and ambitions are realized. to mitigate aversive airborne sub-pheromone methyl esters (almost certainly the cause of artificial aversive emotions), we will be trying several attenuation strategies. staff collecting, storing, and dispensing pheromone (and placebo) will utilize the provided 3m versaflo supplied air carbon filtered respirator for pharmaceutical applications. collection from volunteer pheromone donors and administration to tox screened opioid addicts will be in areas ventilated by dyson carbon-filtered oscillating fans placed to break up plumes of airborne sub-pheromone sufficiently to attenuate aversive emotion. other lab techniques will also be tried as artificially stimulated emotional and heartfelt complaints are expected, from everybody. unfortunately, the rapid process of healing opioid addiction will involve the unavoidable creation of potentially problematic emotions. we will try smaller daily doses, reverse fisher esterification with apple cider vinegar, more vigorous air disturbances, negative air pressure, fume hoods, isolation, etc.

Eligibility criteria:
inclusion criteria: dirty tox screen showing recent and continuing opioid drug dependence - exclusion criteria: pregnant people, people who desire to retain their paraphilia -
adherence of apixaban and warfarin in patients with arterial fibrillation in real-world setting in sweden

Conditions: Anticoagulation

Summary: this will be a retrospective cohort study using national register linkage data (including prescription, inpatient, mortality, and socioeconomic data). the study period will be from may 29, 2013 to june 30, 2015. patients will be followed from the start of treatment (index date) until their death, exiting the database, or until the end of the study period (june 30, 2015).


Eligibility criteria:
inclusion criteria: * for the af cohort * patients that have ≥1 af diagnosis registered in the patient register * apixaban subcohort 1 * patients eligible for the af cohort * patients that had a first prescription for apixaban during the identification period without previous prescriptions for noacs or warfarin during the preceding 12 months * warfarin subcohort 1 * patients eligible for the af cohort * patients that had a first prescription for warfarin during the identification period without previous prescriptions for noacs or warfarin during the preceding 12 months * apixaban subcohort 2 * patients eligible for the af cohort * patients that had a first prescription for apixaban during exclusion criteria: * for the af cohort: * patients with valvular af will be excluded (see definition appendix 1) * warfarin subcohort 1: * patients will be excluded from this sub-cohort if they had at least one prescription for warfarin or noacs during the 12-month period preceding the first prescription for warfarin during the identification period, ie, the index date